Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 18];1(3.1):s24. Available from: https://skin.dermsquared.com/skin/article/view/119